Cochrane · systematic review · CD005415
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding
Kanno, T, Yuan, Y, Tse, F, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 1 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Proton pump inhibitor treatment compared to H2RA, placebo or no treatment in people with upper gastrointestinal bleeding prior to endoscopic diagnosis
Population: people with upper gastrointestinal bleeding prior to endoscopic diagnosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality ‐ within 30 days Proton pump inhibitor treatment vs H2RA, placebo or no treatment | OR 1.14 [0.76, 1.7] | 5 studies · 2143 participants | Low Downgraded: risk of bias, imprecision |
Rebleeding ‐ within 30 days Proton pump inhibitor treatment vs H2RA, placebo or no treatment | OR 0.81 [0.62, 1.06] | 5 studies · 2121 participants | Low Downgraded: risk of bias, imprecision |
Surgery ‐ within 30 days Proton pump inhibitor treatment vs H2RA, placebo or no treatment | OR 0.91 [0.65, 1.26] | 6 studies · 2223 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants with stigmata of recent haemorrhage at index endoscopy Proton pump inhibitor treatment vs H2RA, placebo or no treatment | OR 0.8 [0.52, 1.21] | 4 studies · 1332 participants | Low Downgraded: risk of bias, imprecision |
Endoscopic haemostatic treatment at index endoscopy Proton pump inhibitor treatment vs H2RA, placebo or no treatment | OR 0.68 [0.5, 0.93] | 3 studies · 1983 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |